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Abstract
Background: Histone deacetylase (HDAC) inhibitors, developed as promising anti-tumor drugs, exhibit their anti-
inflammatory properties due to their effects on reduction of inflammatory cytokines.
Objective: To investigate the protective effect of butyrate, a HDAC inhibitor, on lipopolysaccharide (LPS)-induced
acute lung injury (ALI) in mice.
Methods: ALI was induced in Balb/c mice by intratracheally instillation of LPS (1 mg/kg). Before 1 hour of LPS
administration, the mice received butyrate (10 mg/kg) orally. The animals in each group were sacrificed at different
time point after LPS administration. Pulmonary histological changes were evaluated by hematoxylin-eosin stain and
lung wet/dry weight ratios were observed. Concentrations of interleukin (IL)-1b and tumor necrosis factor (TNF)-a
in bronchoalveolar lavage fluid (BALF) and concentrations of nitric oxide (NO) and myeloperoxidase (MPO) activity
in lung tissue homogenates were measured by enzyme-linked immunosorbent assay (ELISA). Expression of nuclear
factor (NF)-B p65 in cytoplasm and nucleus was determined by Western blot analysis respectively.
Results: Pretreatment with butyrate led to significant attenuation of LPS induced evident lung histopathological
changes, alveolar hemorrhage, and neutrophils infiltration with evidence of reduced MPO activity. The lung wet/dry
weight ratios, as an index of lung edema, were reduced by butyrate administration. Butyrate also repressed the
production of TNF-a, IL-1b and NO. Furthermore, the expression of NF-B p65 in nucleus was markedly suppressed
by butyrate pretreatment.
Conclusions: Butyrate had a protective effect on LPS-induced ALI, which may be related to its effect on
suppression of inflammatory cytokines production and NF-B activation.
Background
Acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) are well defined and readily recog-
nised clinical disorders caused by many clinical insults
to the lung or because of predispositions to lung injury
[1]. Sepsis and pneumonia are the main causes of ALI
clinically. ALI occurring during gram-negative bacterial
pneumonia and sepsis is caused in large part by lipo-
polysaccharide (LPS), a component of the cell walls of
gram-negative bacteria [2]. When the cells in lung are
exposed to LPS, the nuclear factor (NF)-B is activated.
NF-B is a protein transcription factor that functions to
enhance the transcription of a variety of genes, including
cytokines and growth factors, adhesion molecules,
immunoreceptors, and acute-phase proteins [3]. Upon
activation by LPS, NF-B is required for maximal tran-
scription of many cytokines, including tumor necrosis
factor (TNF)-a, interleukin (IL)-1b, IL-6, and IL-8,
which are thought to be important in the generation of
ALI. These cytokines and chemokines contribute to the
vigorous recruitment of neutrophils in lung. Therefore,
ALI is substantially caused by excessive neutrophil- and
cytokine-mediated inflammation. Despite advancement
in understanding the pathophysiology of ALI/ARDS and
improved therapy methods, however, mortality rates of
ALI/ARDS are around 40% [4].
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Histone deacetylases (HDACs) regulate gene expres-
sion. In general, inhibitors of HDACs result in a non-
specific increase in gene expression. Therefore, they are
considered as a new class of therapeutic agents for the
treatment of tumor [5]. Agents such as trichostatin A
(TSA) or suberoylanilide hydroxamic acid (SAHA)
induce differentiation and/or apoptosis of transformed
cells in vitro and inhibit tumor growth in vivo [6]. An
unexpected effect of HDAC inhibitors, however, was
revealed by recent studies indicating that they are able
to suppress transcription and reduce inflammatory cyto-
kines in models of autoimmune and inflammatory dis-
eases [7,8]. Butyrate, a HDAC inhibitor, is a short-chain
fatty acid derived from bacterial metabolism of dietary
fibers in the colon and produces cell cycle arrest, differ-
entiation and/or apoptosis of colorectal cancer cells in
vitro [9-13]. Previous study has shown that butyrate
reduced inflammation in Crohn’s disease through NF-
B inhibition [14]. To date, unfortunately, the protective
role of HDAC inhibitors in ALI is not well
characterized.
The aims of this study were to investigate whether
butyrate reduces inflammation in LPS-induced ALI
in mice and to determine whether the protective effect
is produced by suppression of inflammatory cytokines
production and NF-B activation.
Materials and methods
Animals and Reagents
Male BALB/C mice weighing 20-25 g were purchased
from the Animal Center of the Fourth Military Medical
University (Xian, China). All animals were allowed to
take food and tap water ad libitum. All procedures were
in accordance with the Declaration of Helsinki of the
World Medical Association. The protocols were also
approved by the Institutional Animal Care and Use
Committee of the Fourth Military Medical University
Tangdu Hospital. LPS (Escherichia coli lipopolysacchar-
ide, 055:B5) and butyrate were obtained from Sigma
Chemical Company (St. Louis, MO., USA), and were
respectively dissolved in saline (1 mg/ml and 2 mg/ml).
Enzyme-linked immunosorbent assay (ELISA) kits of
TNF-a, IL-1b, myeloperoxidase (MPO) and nitric oxide
(NO) were purchased from R&D Corporation (R&D
Systems Inc. Minneapolis, MN, USA). Antibodies speci-
fic for total NF-B p65, Lamin B and b-actin were
obtained from the Wuhan Boster Biological Technology,
Ltd. (Wuhan, China). Nuclear and cytoplasmic protein
extraction kit was purchased from Beyotime Institute of
Biotechnology (Beijing, China). BCA protein assay kit
was obtained from Thermo Scientific Pierce Protein
Research Products (Rockford, IL., USA).
Experimental Protocol
All animals were randomly divided into 4 groups (n =
15, each group). Group 1 (control group) received an
intratracheal injection of saline, group 2 (butyrate
group) received an intragastric injection of butyrate (10
mg/kg), group 3 (LPS group) received an intratracheal
instillation of LPS (1 mg/kg), and group 4 (LPS + buty-
rate group) received an intragastric injection of buty-
rate (10 mg/kg) 1 hour before LPS administration. At
different time point (1, 3, 6, 12 and 24 hours) after
administration, all animals were sacrificed. Bronchoal-
veolar lavage (BAL) was performed through the left
lung. The superior lobe of right lung was excised for
histopathologic examination. The middle lobe of right
lung was excised for analysis of lung wet/dry weight
ratio. The lower lobe of right lung was rapidly removed
and cut into two parts in same size. A part of the
lower lobe was homogenized and frozen in a cold
phosphate solution at -80°C for MPO and NO analysis,
and the another part was used to extract cytoplasmic
and nuclear proteins for Western blot analysis.
BAL
Animals were anesthetized with intraperitoneal pento-
barbital (50 mg/kg). A median sternotomy allowed for
exposure of both of the lungs. The trachea was exposed
and inserted with an intravenous infusion needle. After
ligating the hilum of right lung, the left lung was
lavaged 5 times with 0.5 ml ice-cold phosphate buf-
fered saline. The recovery ratio of the fluid was about
90%. The BAL fluid (BALF) was immediately centri-
fuged at 500 × g for 10 minutes at 4°C, and the cell-
free supernatant was stored at -80°C for analysis of
cytokines.
MPO and NO Assays
To carry out the assays, tissue samples were subjected
to three further freeze-thaw cycles and centrifuged at
12 000 × g for 10 minutes at 4°C. The supernatant was
assayed for MPO activity and NO concentrations with
ELISA kits. All procedures were done in accordance
with the manufacturer’s instructions.
TNF-a and IL-1b Assays
Concentrations of TNF-a and IL-1b in BALF were mea-
sured by using ELISA kits. All procedures were done in
accordance with the manufacturer’s instructions.
Lung wet/dry weight ratio
As an index of lung edema, the amount of extravascular
lung water was calculated. The middle lobe of right lung
was excised and the wet weight was recorded. The lung
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was then placed in an incubator at 80 °C for 24 hours to
obtain the dry weight. And the wet/dry weight ratios
were calculated by dividing the wet weight by the dry
weight.
Pulmonary Histopathology
The superior lobe of right lung was harvested at 24
hours after LPS administration and fixed with an intra-
tracheal instillation of 1 ml buffered formalin (10%, PH
7.2). The lobe was further fixed in 10% neutral buffered
formalin for 24 hours at 4°C. The tissues were
embedded in paraffin and cut into 5 μm sections.
Hematoxylin-eosin stains were performed using stan-
dard protocol.
Western Blot Analysis
The lower lobe of right lung in each mouse was har-
vested separately at 1, 3, 6, 12 and 24 hours after LPS
administration and frozen in liquid nitrogen immedi-
ately until homogenization. Tissue samples were homo-
genized and the cytoplasmic and nuclear proteins were
extracted respectively according to instructions of
Nuclear and Cytoplasmic Protein Extraction Kit. Protein
concentrations were determined by BCA protein assay
kit. Samples were separated on a denaturing 12% pol-
yacrylamide gel and transferred to a nitrocellulose
membrane. NF-B p65 protein was detected by chemi-
luminescence using a rabbit polyclonal antibody accord-
ing to the manufacturer’s instructions.
Statistical analyses
Data were entered into a database and analyzed using
SPSS software, and expressed as means ± SEM. Statisti-
cally significant differences between groups were deter-
mined by ANOVA followed by Student’s t test.
Significance was accepted when p < 0.05.
Results
Effect of Butyrate on MPO Activity and NO
Concentrations in Lung Tissues of Mice with ALI
After LPS administration, the MPO activity in lung tis-
sues was significantly and continuously increased com-
pared with the control and butyrate groups from 1 to
24 hours (fig. 1A). In addition, the concentrations of
NO were significantly increased at 1 hour and peaked at
3 hours after LPS administration (fig. 1B). However, in
LPS + butyrate group, butyrate pretreatment markedly
decreased the MPO activity and NO concentrations at
different time point (fig. 1A and 1B).
Effect of Butyrate on the Concentrations of TNF-a and
IL-1b in BALF of Mice with ALI
The concentrations of TNF-a and IL-1b in BALF were
significantly increased at 1 hour and peaked at 3 hours
after LPS administration (fig. 2A and 2B). Butyrate pre-
treatment efficiently reduced the production of TNF-a
and IL-1b at different time point (fig. 2A and 2B).
Effect of Butyrate on the Lung edema of Mice with ALI
Compared with the control and butyrate groups, the
lung wet/dry weight ratios were significantly and con-
tinuously increased from 1 to 24 hours after LPS admin-
istration. The increase of the lung wet/dry weight ratios
was significantly reduced by butyrate administration at
different time point (fig. 3).
Effect of Butyrate on the Pulmonary Histopathological
Changes of Mice with ALI
Lung tissues from the control and butyrate groups
showed a normal structure and no histopathological
changes under a light microscope (fig. 4A and 4B). In
LPS group, the lungs stained with hematoxylin-eosin
indicated widespread alveolar wall thickness caused by
Figure 1 Effect of butyrate on MPO activity and NO concentrations in lung tissues of mice with ALI. A. The MPO activity in lung tissues
at each time point after LPS administration and the effect of butyrate pretreatment. B. The concentrations of NO in lung tissues at each time
point after LPS administration and the effect of butyrate pretreatment. Data are expressed as mean ± SEM, *P < 0.05 vs. control and butyrate
group; #P < 0.05 vs. LPS group.
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edema, severe hemorrhage in the alveolus, alveolus col-
lapse and obvious inflammatory cells infiltration (fig. 4C).
In LPS + butyrate group, the histopathological changes of
lung were minor compared with those in LPS group,
especially in inflammatory cells infiltration (fig. 4D).
Effect of Butyrate on the Activation of NF-B in Lung
Tissues of Mice with ALI
After LPS administration, the expression of NF-B p65
in nucleus markedly increased and peaked at 3 hours
(fig. 5B and 5D). The expression of NF-B p65 in
nucleus induced by LPS was significantly suppressed at
1, 3 and 6 hours by butyrate pretreatment (fig. 5C and
5D). On the contrary, the expression of NF-B p65 in
cytoplasm was significantly reduced by LPS administra-
tion (fig. 6B and 6D), and these changes were inhibited
by butyrate pretreatment (fig. 6C and 6D). No changes
of expression of NF-B p65 in cytoplasm (fig. 6A and
6D) and nucleus (fig. 5A and 6D), same as control
group, were observed with administration of butyrate
alone at each time point.
Discussion
The different results were observed in previous studies
in vitro in terms of HDAC inhibitors’ anti-inflammatory
effects. ITF2357, a HDAC inhibitor, reduced IL-1, TNF-
a and interferon-g expression in LPS-stimulated human
peripheral blood mononuclear cells [15]. Butyrate also
reduced IL-12 production by human blood monocytes,
and inhibited NO production in RAW macrophage cells
[16,17]. However, pharmacological inhibition of HDAC
increased the release of the pro-inflammatory cytokine
IL-8 in human alveolar epithelial cells (A549) treated by
TNF-a [18]. Moreover, TSA enhanced IL-8 production
in SV-40-transformed lung epithelial cells stimulated by
LPS [19].
Based on the results observed in lung epithelial cells,
HDAC inhibitors seemed to be pro-inflammatory in
ALI. In the present study, interestingly, our results indi-
cated that administration of butyrate in vivo attenuated
pulmonary inflammation in LPS-induced ALI. The rea-
son for the discrepancy may be related to the different
circumstances in vitro and in vivo. Furthermore,
although the alveolar epithelial cells are the main part of
lung tissues, the alveolar macrophages and neutrophils
play a central role in ALI but not alveolar epithelial
cells, which may contribute to the discrepancy. Consis-
tent with the present study, TSA attenuated the devel-
opment of allergic airway inflammation by decreasing
expression of the Th2 cytokines, IL-4 and IL-5, reduced
spinal cord inflammation, demyelination, neuronal and
axonal loss, and ameliorated disability in the relapsing
phase of experimental autoimmune encephalomyelitis, a
model of multiple sclerosis [20,21]. Therefore, different
Figure 2 Effect of butyrate on the concentrations of TNF-a and IL-1b in BALF of mice with ALI. A. The concentrations of TNF-a in BALF at
each time point after LPS administration and the effect of butyrate pretreatment. B. The concentrations of IL-1b in BALF at each time point after
LPS administration and the effect of butyrate pretreatment. Data are expressed as mean ± SEM, *P < 0.05 vs. control and butyrate group;
#P < 0.05 vs. LPS group.
Figure 3 Effect of butyrate on the lung edema of mice with
ALI. At each time point after LPS administration, pretreatment of
butyrate decreased lung wet/dry ratios markedly. Data are
expressed as mean ± SEM, *P < 0.05 vs. control and butyrate
group; #P < 0.05 vs. LPS group.
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from the variable results observed in vitro, HDAC inhi-
bitors are more likely to exert their anti-inflammatory
effects in vivo.
NF-B pathway has been considered to play a pivotal
role in the pathogenesis of ALI. NF-B is normally
retained in the cytoplasm in an inactive form through
being associated with an inhibitor of B (IB) protein
[22]. NF-B is activated by a variety of pathogens
known to cause inflammation and sepsis, including LPS.
Following activation, the IB protein breaks down and
liberates NF-B to enter the nucleus where it binds to
specific sequences in the promoter/enhancer regions of
genes [23,24]. Thus, NF-B improves the transcription
of most pro-inflammatory molecules, including adhesion
molecules, enzymes, cytokines, and chemokines. Among
these pro-inflammatory molecules, TNF-a and IL-1b are
the most important cytokines in the pathogenesis of
ALI. Elevated concentrations of TNF-a and IL-1b have
been measured in BALF from patients with ARDS, and
were related to prognosis [25,26]. Because TNF-a and
IL-1b can stimulate the production of a variety chemo-
tatactic cytokines such as IL-8, epithelial cell neutrophil
activator (ENA-78), monocyte chemotactic peptide, and
macrophage inflammatory peptide-1a (MIP-1a), they
have earned a position of prominence at the head of the
inflammatory cytokine cascade [27]. Therefore, the inhi-
bition of TNF-a and IL-1b showed the reduction of pul-
monary injury in ALI induced by LPS in mice [28,29].
In the present study, the concentrations of TNF-a and
IL-1b in BALF and the expression of NF-B p65 in
nucleus increased significantly after LPS administration,
and reached their peak at 3 hours respectively. Pretreat-
ment of butyrate markedly reduced the concentrations
of TNF-a and IL-1b in BALF, and suppressed the
expression of NF-B p65 in nucleus. In addition, we
also found that in ALI mice the elevated MPO activity,
a specific granulocyte enzyme, was significantly reduced
by butyrate pretreatment. Although neutrophils have
beneficial actions in eradicating microbial infections,
excessive neutrophil accumulation in lung contributes to
the development of ALI. The cytokines secreted by
alveolar macrophages, such as TNF-a and IL-1b, play a
key role in neutrophil recruitment to the lung. There-
fore, the reduced neutrophils infiltration in lung by
butyrate administration was partially due to its inhibi-
tory effect on cytokines production.
In our study, we also found the reduced expression of
NF-B in cytoplasm due to the enhanced NF-B nuclear
translocation after LPS administration, which was mark-
edly inhibited by butyrate pretreatment. Previous study
showed that butyrate pretreatment of a human colon
cell line (HT-29 cells) inhibited the TNF-a-induced
nuclear translocation of the pro-inflammatory transcrip-
tion factor NF-B in part by preventing the complete
degradation of IB-a by reducing proteasome activity in
the cell [30]. Moreover, butyrate decreased TNF produc-
tion and pro-inflammatory cytokine mRNA expression
by intestinal biopsies and lamina propria cells from
Crohn’s disease patients, and abolished LPS induced
expression of cytokines by peripheral blood
Figure 4 Effect of butyrate on the pulmonary histopathological changes of mice with ALI. Lung sections stained with hematoxylin-eosin
from 24 hours after LPS administration revealed pulmonary histopathological changes (original magnification ×200). A. control group: normal
structure. B. butyrate group: same as control group. C. LPS group: alveolar wall thickness, hemorrhage, alveolus collapse and obvious
inflammatory cells infiltration. D. LPS + butyrate group: minor histopathological changes compared with LPS group.
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mononuclear cells and transmigration of NF-B from
the cytoplasm to the nucleus [14]. In the RAW 264.7
murine macrophage cells stimulated by LPS, butyrate
down-regulated NO production and prevented the acti-
vation of NF-B through the stabilization of IB-a and
IB-b [31]. These results observed in vitro suggested
that the anti-inflammatory effects of butyrate in ALI
may primarily rely on inhibition of IB degradation, and
consequently inhibiting the nuclear translocation of NF-
B and the production of cytokines regulated by NF-B.
Pulmonary edema is a life-threatening condition that
frequently leads to acute respiratory failure. Injury to
the alveolar epithelium can disrupt the integrity of the
alveolar barrier or down-regulate ion transport path-
ways, thus, reducing net alveolar fluid reabsorption and
enhancing the extent of alveolar edema [32]. Here we
observed a significant reduction of pulmonary injury
and edema in lungs of ALI mice treated by butyrate.
Therefore, butyrate possessed the protective effect on
ALI, which implied the clinical use of butyrate in future.
In the present study, the administration of butyrate
was applied orally not intranasally. Butyrate is an anti-
tumor agent, so it is cytotoxic. Therefore, the intranasal
delivery of butyrate may be harmful to the nasal
mucosa. Furthermore, the nasal absorption of butyrate
by each mouse would be different due to the influence
of respiration. Because of these, we considered that
intragastric injection of butyrate might be a more appro-
priate form of administration in this study. Moreover,
our results showed that this form of administration was
feasible and effective. In addition, we only investigated
Figure 5 Effect of butyrate on the nuclear expression of NF-B
in lung tissues of mice with ALI. A., B. and C. Representative
Western blots showed the nuclear expression of NF-B p65 in lung
tissues in different groups. D. Mean ± SEM NF-B p65 optical
densitometry from different groups. Pretreatment of butyrate
significantly repressed the expression of NF-B p65 in nucleus at 1,
3 and 6 hours after LPS administration. Data are expressed as mean
± SEM, *P < 0.05 vs. control and butyrate group; #P < 0.05 vs. LPS
group.
Figure 6 Effect of butyrate on the cytoplasmic expression of
NF-B in lung tissues of mice with ALI. A., B. and C.
Representative Western blots showed the cytoplasmic expression of
NF-B p65 in lung tissues in different groups. D. Mean ± SEM NF-B
p65 optical densitometry from different groups. The expression of
NF-B p65 in cytoplasm was significantly reduced by LPS
administration and these changes were inhibited by butyrate
pretreatment. Data are expressed as mean ± SEM, *P < 0.05 vs.
control and butyrate group; #P < 0.05 vs. LPS group.
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the protective effect of butyrate on ALI on the condition
that butyrate was administrated before LPS exposure,
which was not often possible clinically. Given that pro-
inflammatory cytokines TNF-a and IL-1b were released
within hours after onset of ALI, early butyrate treatment
after LPS exposure should be protective. Thus, in the
further study, we will evaluate the protective effect of
delayed butyrate treatment on ALI, and also investigate
the optimal time window and dose of delayed butyrate
treatment.
In conclusion, we have provided the first evidence that
pretreatment of butyrate significantly attenuated pul-
monary inflammation in LPS-induced ALI in mice.
Thus, they might be useful in situations where current
anti-inflammatory therapies are unsatisfactory.
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